Date: 2011-06-17
Type of information: Grant
Company: TcLand Expression (France)
Investors: Oseo (France) - European Regional Development Fund (ERDF)
Amount: € 1.2 million
Funding type: french and european grants
Planned used: These grants will be used to accelerate the validation of a molecular test to predict non-response to anti-TNF treatment (in particular infliximab Remicade®) in Rheumatoid Arthritis patients. The test was developed using blood samples from cohorts of European, US and Japanese patients. The opportunity to clinically validate the test on patients from different continents will allow TcLand Expression to target international markets.
Others: The biotech company TcLand Expression is pleased to announce the financial support awarded by Oseo and the European Regional Development Fund (ERDF) for the validation study of the first companion diagnostic test in rheumatoid arthritis. The program is mainly dedicated to setting up a prospective European multicentre clinical trial to validate the diagnostic performance of a molecular test to predict non-response to anti-TNF treatment (in particular infliximab Remicade®) in Rheumatoid Arthritis patients.
This test will have a major impact on patients suffering from Rheumatoid Arthritis, a chronic disease that affects one in a hundred people in western countries. Studies have shown that as much as 30% of RA patients do not respond or respond adequately to TNF inhibitors, a burden for healthcare systems that will reach several billion euros in the coming decade. The test could therefore become a cornerstone to prevent therapeutic failure and allows clinicians to immediately select an alternative treatment for their patients.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
